Trial Profile
A study to evaluate whether the results of second line sunitinib therapy related to duration of response of first line imatinib in patients with advanced gastrointestinal stromal tumors (GIST).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Sep 2015
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary) ; Imatinib
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- 04 Sep 2015 Status changed from not stated to completed.
- 20 Jul 2015 New trial record
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.